Melanoma clinical trials also demonstrated increased rates of cardiac toxicity including decreased ejection fractions for patients receiving trametinib. Implications for Practice Neurofibromatosis type 1 (NF1) clinical care is on the cusp of a transformative shift. With the success of recent clinical trials using MEK inhibitors, an increasing number of NF1 patients are being treated with MEK inhibitors for both plexiform neurofibromas and low\grade gliomas. The use of MEK inhibitors is likely to increase substantially in NF1. Given these changes, the Clinical Care Advisory Board of the Children’s Tumor Foundation has identified a need within the NF1 clinical community for guidance for the safe and effective Rabbit Polyclonal to PKC delta (phospho-Ser645) use of MEK inhibitors for NF1\related tumors. This article provides a review of the published experience of MEK inhibitors in NF1 and provides recommendations for monitoring and management of Rigosertib side effects. gene. Neurofibromin is a ras\GAP protein, a negative regulator of RAS signaling. Loss of functional neurofibromin results in activation of the classic RAS\MAPK signaling cascade, cell proliferation, and subsequent tumor formation. NF1 is a classic tumor suppressor disorder, with tumor cells demonstrating biallelic loss of the functional gene. Mitogen\activated protein kinase kinase (MEK1/MEK2) is a kinase in the RAS\MAPK pathway, which phosphorylates and activates MAPK (mitogen\activated protein kinase). Overactivation of the RAS\MAPK signaling cascade has been implicated in the development of a number of malignancies; perhaps the most well known is melanoma. In melanoma, inhibition of the signaling pathway components RAF and MEK results in improved response rates and overall survival in Rigosertib comparison with conventional chemotherapy or BRAF inhibitors alone 3, 4, 5, 6. Clinical trials evaluating MEK inhibitors in NF1 patients with two different tumor types, low\grade gliomas and plexiform neurofibromas, have shown encouraging results. Table ?Table11 outlines the NF1\specific recently published or ongoing clinical trials. As an overall well\tolerated treatment for NF1\associated complex and inoperable tumors, MEK inhibitor therapy is likely to become more widely used in the NF1 population. To aid clinicians who may not have experience with the use of this class Rigosertib of agents, the Clinical Care Advisory Board of the Children’s Tumor Foundation has developed this review to present an overview of the use of MEK inhibitors in the Rigosertib NF1 population, covering relevant clinical trial results, common side effects, basic symptom management, recommended screening guidelines, and patient counseling approaches. Table 1 Current state of MEK inhibitor trials in neurofibromatosis type 1 cells. These tumors can arise along any group Rigosertib of peripheral nerves and can result in significant morbidity such as pain, disfigurement, neurological deficits, and local organ compromise. PNs are thought to be congenital, often becoming clinically apparent in young childhood, with the most rapid growth occurring prior to the adult years 23, 24. PNs are also associated with a risk of malignant transformation to malignant peripheral nerve sheath tumors, the leading cause of mortality in NF1 25, 26, 27. Until recently, therapy for PNs was limited to surgical debulking, which is often associated with subtotal resection, plexiform regrowth, and significant surgical risks 28, 29. Hence, there is a clear need for effective medical therapy for these tumors. As with LGGs, early\phase plexiform clinical trials have shown promising response with the use of MEK inhibitors. In 2016, Dombi et al. demonstrated that inhibition of MEK with the oral inhibitor selumetinib in pediatric NF1\associated PNs resulted in >20% volumetric tumor shrinkage in 70% of patients 30. Response to selumetinib therapy in NF1\associated PNs was further demonstrated in a phase II study (SPRINT) that showed improvement in motor skills as well as plexiform\related quality of life measures such as pain 31. In response to the results of these early studies, selumetinib has been granted orphan drug status by the Food and Drug Administration (FDA) and is currently undergoing the process of FDA approval. Mirdametinib, formerly known as PD\0325901, has also received orphan drug status by the FDA for treatment of NF1 associated plexiform neurofibromas. In a phase II study in adolescents and young adults, 19 patients were treated and 42% demonstrated an objective response of >20% shrinkage in tumor volume 32. Finally, in a phase II study of the MEK inhibitor trametinib, at least 50% of patients met the partial response target of >20% plexiform volume reduction 33. Other trials using MEK inhibitors in NF1 are currently underway, including binimetinib for PNs in both pediatric and adult NF1 patients. Of note, when assessing plexiform growth as well as treatment response in clinical trials, volumetric analysis is more sensitive in assessment of.